OmniAb, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OABI research report →
Range $4 – $4
Price Chart
About the company
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments.
- CEO
- Matthew W. Foehr
- IPO
- 2021
- Employees
- 89
- HQ
- EmeryVille, CA, US
Get TickerSpark's AI analysis on OABI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $679.71M
- P/E
- -13.71
- Fwd P/E
- 37.78
- PEG
- -0.24
- P/S
- 16.91
- P/B
- 2.42
- EV/EBITDA
- -31.30
- Div Yield
- 0.00%
- Gross Margin
- 63.58%
- Op Margin
- -115.83%
- Net Margin
- -108.17%
- ROE
- -16.73%
- ROIC
- -16.42%
Latest fiscal year · YoY change
- Revenue
- $18.67M-29.3%
- Gross Profit
- $-3,391,000-112.8%
- Op Income
- $-71,518,000
- Net Income
- $-64,779,000-4.4%
- EPS
- $-0.57+6.6%
- OCF Growth
- +8.1%
- FCF Growth
- +10.9%
- 52W High
- $5.45
- 52W Low
- $1.35
- 50D MA
- $4.82
- 200D MA
- $2.94
- Beta
- 1.05
- RSI (14)
- 43
- Avg Volume
- 1.46M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
OmniAb delivered stronger Q3 revenue on services and xPloration, raised full-year guidance, and pointed to a growing partner pipeline plus new deal activity as key drivers.· October 30, 2026
- Q3 revenue was $4 million, up from $2.2 million a year ago, driven mainly by service revenue and xPloration.
- Net loss improved to $15.7 million, or $0.12 per share, from $16.5 million, or $0.14 per share last year.
- OmniAb raised 2026 revenue guidance to $35 million-$39 million and year-end cash guidance to $53 million-$57 million.
- The company ended Q3 with 111 active partners and 433 active programs, with more than $3 billion in contracted potential milestones and an average royalty rate of about 3.4%.
- Management highlighted the new Lilly ion-channel deal, which carries up to $370 million in potential milestones plus tiered royalties, and said batoclimab’s recent China approval adds another approved asset from the platform.
Revenue for the third quarter of 2026 was $4 million, compared with $2.2 million in the prior-year period, with growth driven primarily by service and xPloration revenue. For the 9-month period, revenue was $31.8 million versus $10.3 million in the same period of 2025, mainly due to milestone revenue. Total cost and operating expense was $20.4 million in the quarter, flat year over year, and the net loss improved to $15.7 million, or $0.12 per share, from $16.5 million, or $0.14 per share. Year-to-date net loss improved to $29.3 million, or $0.23 per share, from $50.6 million, or $0.46 per share. Cash and investments ended the quarter at $64.2 million. Management raised 2026 revenue guidance to $35 million-$39 million from $32 million-$36 million, lowered cost and operating expense guidance to $83 million-$87 million, lowered cash cost and operating expense guidance to $50 million-$54 million, and now expects year-end cash of $53 million-$57 million. xPloration revenue is expected to be between $2 million and $3 million in 2026, with revenue expected to double in 2027 and double again in 2028.
CEO Matt Foehr emphasized that OmniAb’s model is built around diversified, durable revenue streams from partnerships, milestones, royalties, and newer technology offerings. He framed the quarter as evidence that the company’s differentiated platforms are gaining traction, citing the Lilly ion-channel deal, broader partner adoption of OmnidAb and OmniUltra, and the rollout of xPloration and OmniTides. His tone was upbeat and confident, repeatedly stressing that the company is positioned to create long-term value through both existing and new licensing pathways.
CFO Kurt Gustafson said Q3 revenue rose to $4 million from $2.2 million, largely from service and xPloration, while operating expense stayed flat at $20.4 million. He noted the quarter’s net loss improved to $15.7 million and that year-to-date operating expense fell to $62.7 million from $63.5 million, reflecting efficiency gains. He also highlighted cash and investments of $64.2 million and explained that deferred revenue increased because of the upfront payment from the new ion-channel agreement. On guidance, he raised 2026 revenue to $35 million-$39 million, trimmed operating expense guidance, and said the company expects to end the year with $53 million-$57 million in cash, implying roughly breakeven net cash flow for 2026.
Analysts focused on what is driving service revenue, how fast xPloration can scale, and when batoclimab, TEV-'408, and other partnered programs might translate into more economics for OmniAb. Management said service revenue reflects both new ion-channel work and increasing use of OmnidAb and OmniUltra, and that Lilly should begin contributing in Q4. On xPloration, they said the instrument sales pipeline can run 12 to 18 months, most current revenue is from instrument placements, and recurring consumable/software/service revenue should build over time. They also said TEV-'408’s celiac and vitiligo data look encouraging, but monetization timing remains deal-specific, while batoclimab’s China approval is too early to size for royalties.
The company is seeing multiple growth drivers at once: milestone-rich partner progress, a new Lilly collaboration, growing service work, and an early but expanding xPloration business. Management also pointed to a large base of contracted economics — more than $3 billion in potential milestones and 34 active clinical programs — with near-term clinical readouts that could unlock additional payments.
xPloration is still early, and management said it is too soon to know whether consumable pull-through has stabilized or how large the long-term recurring revenue mix will be. Royalties from batoclimab are also too early to size, and management said TEV-'408 and other partnered assets remain subject to deal-specific milestone structures and timing. Even with better operating efficiency, the company is still guiding to a net cash outflow-roughly breakeven year and relies heavily on milestone timing for near-term revenue.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.5%
- Shares Outstanding
- 145.86M
- Float Shares
- 118.80M
of shares held by institutions
135 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Whitefort Capital Management, LP | 10.14M | ▼ 104.00K |
| Blackrock, Inc. | 9.73M | ▲ 834.32K |
| Vanguard Group Inc | 5.63M | ▲ 477.14K |
| Nomura Holdings Inc | 5.03M | ▼ 929 |
| Cadian Capital Management, LP | 4.21M | 0 |
| Vanguard Capital Management LLC | 3.76M | ▼ 91.16K |
| Geode Capital Management, LLC | 2.81M | ▼ 69.84K |
| Rice Hall James & Associates, LLC | 2.54M | ▼ 72.24K |
| State Street Corp | 2.28M | ▲ 143.46K |
| Private Management Group Inc | 2.01M | ▼ 331.31K |
| Arrowstreet Capital, Limited Partnership | 1.85M | ▲ 1.69M |
| Prudential Financial Inc | 1.41M | ▲ 1.38M |
Held by 179 ETFs
Biggest fund positions in OABI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 1, 26 | Love Steven | other | 13,334 |
| Nov 1, 26 | Love Steven | other | 13,334 |
| Aug 1, 26 | Nwachuku Amechi Ekeke | other | 800,000 |
| Jul 13, 26 | Nwachuku Amechi Ekeke | other | 0 |
| Jun 17, 26 | Bertozzi Carolyn R | other | 20,000 |
| Jun 17, 26 | Bertozzi Carolyn R | other | 40,000 |
| Jun 17, 26 | Bertozzi Carolyn R | other | 20,000 |
| Jun 17, 26 | Bertozzi Carolyn R | other | 20,000 |
| Jun 17, 26 | Cochran Jennifer R. | other | 20,000 |
| Jun 17, 26 | Cochran Jennifer R. | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OABI coverage
Recent articles, reports, and earnings notes.
No research on OABI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OABI report →OmniAb: A Self-Funding Option Book On 433 Partner Programs
seekingalpha.com · Oct 31
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 30
OmniAb Q3 Earnings Call Highlights
marketbeat.com · Oct 30
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Oct 30
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
businesswire.com · Oct 30
OmniAb to Participate in Upcoming Investor Conferences in November
businesswire.com · Oct 26
OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
marketbeat.com · Oct 25
OmniAb to Report Third Quarter 2026 Financial Results on October 30
businesswire.com · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.